Granted Patent
B2
US 12,496,308 · App. 18/492,750 · Granted Dec 16, 2025
Methods of administering a pharmaceutically acceptable salt of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate
Inventors:
Marc F. Pelletier (Shaker Heights, OH); Paul Robert McGuirk (Spring Hill, FL); George William Farr (Rocky River, OH)
Assignee:
Aeromics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.
Claims (17)
1 . A method of administering a pharmaceutically acceptable salt of 2-{[3,5-bis (trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate (Formula I)
by injection to a human who has cerebral edema in need thereof, wherein the method comprises mixing the compound of Formula I, an amine, and an aqueous solution, to form a composition and administering the composition thus obtained 24 hours or less after the mixing to the human.
2 . The method of claim 1 , wherein the aqueous solution is sterile water for injection, a sterile solution comprising dextrose, a sterile solution comprising sodium chloride, a sterile solution comprising benzyl alcohol, or Lactated Ringer's.
3 . The method of claim 1 , wherein the amine is tris(hydroxymethyl)aminomethane and/or meglumine.
4 . The method of claim 1 , wherein the composition has a pH between 7.5 and 9.5.
5 . The method claim 1 , wherein the composition has a pH between 8 and 8.5.
6 . The method of claim 1 , wherein the cerebral edema is consequent to a stroke, traumatic brain injury, closed head trauma, or hypoxia.
7 . The method of claim 1 , wherein the cerebral edema is consequent to an ischemic stroke.
8 . The method of claim 6 , wherein the hypoxia is caused by cardiac arrest, stroke, or other interruption of blood perfusion to the brain.
9 . The method of claim 6 , wherein the cerebral edema is cytotoxic cerebral edema.
10 . The method of claim 7 , wherein the cerebral edema is cytotoxic cerebral edema.
11 . The method of claim 1 , wherein the cerebral edema is cytotoxic cerebral edema.
12 . The method of claim 2 , wherein the cerebral edema is cytotoxic cerebral edema.
13 . The method of claim 3 , wherein the cerebral edema is cytotoxic cerebral edema.
14 . The method of claim 4 , wherein the cerebral edema is cytotoxic cerebral edema.
15 . The method of claim 5 , wherein the cerebral edema is cytotoxic cerebral edema.
16 . The method of claim 8 , wherein the cerebral edema is cytotoxic cerebral edema.
Assignments (3)
CERTIFICATE OF CONVERSION
Recorded Jul 20, 2024
From: AEROMICS, LLC
To: AEROMICS, INC.
Reel/Frame 068465/0128 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 15, 2023
From: PELLETIER, MARC F.; MCGUIRK, PAUL ROBERT; FARR, GEORGE WILLIAM
To: AEROMICS, LLC
Reel/Frame 065887/0386 →
ASSIGNEE CHANGE OF ADDRESS
Recorded Dec 15, 2023
From: AEROMICS, INC.
To: AEROMICS, INC.
Reel/Frame 066043/0810 →
Continuity (7)
Continuation
15035006
Provisional Application
61900878
· Nov 6, 2013
Provisional Application
61900919
· Nov 6, 2013
Provisional Application
61900946
· Nov 6, 2013
References Cited (377)
US 3331874A
· Stecker
· 1967
[cited by applicant]
US 3332996A
· Zerweck et al.
· 1967
[cited by applicant]
US 5137871A
· Wei
· 1992
[cited by applicant]
US 5324749A
· Woog et al.
· 1994
[cited by applicant]
US 5486530A
· Boelke et al.
· 1996
[cited by applicant]
US 5519035A
· Maiese et al.
· 1996
[cited by applicant]
US 5741671A
· Agre
· 1998
[cited by applicant]
US 5858702A
· Agre
· 1999
[cited by applicant]
US 5905090A
· Bertolini et al.
· 1999
[cited by applicant]
US 6255298B1
· Lysko et al.
· 2001
[cited by applicant]
US 6500809B1
· Frazer
· 2002
[cited by applicant]
US 7601745B2
· Leban et al.
· 2009
[cited by applicant]
US 7626042B2
· Muto et al.
· 2009
[cited by applicant]
US 7659312B2
· Nakada et al.
· 2010
[cited by applicant]
US 7671058B2
· Tokuyama et al.
· 2010
[cited by applicant]
US 7700655B2
· Muto et al.
· 2010
[cited by applicant]
US 7872048B2
· Simard
· 2011
[cited by applicant]
US 7906555B2
· Flynn et al.
· 2011
[cited by applicant]
US 8003610B2
· Shaw et al.
· 2011
[cited by applicant]
US 8097759B2
· Muto et al.
· 2012
[cited by applicant]
US 8263657B2
· Muto et al.
· 2012
[cited by applicant]
US 8277845B2
· Jacobson et al.
· 2012
[cited by applicant]
US 8946293B2
· Jacobson et al.
· 2015
[cited by applicant]
US 8980952B2
· Simard et al.
· 2015
[cited by applicant]
US 9573885B2
· Pelletier et al.
· 2017
[cited by applicant]
US 9827253B2
· Pelletier et al.
· 2017
[cited by applicant]
US 9949991B2
· Pelletier et al.
· 2018
[cited by applicant]
US 9994514B2
· Pelletier et al.
· 2018
[cited by applicant]
US 20010046993A1
· Ikeda et al.
· 2001
[cited by applicant]
US 20020061311A1
· Haas et al.
· 2002
[cited by applicant]
US 20030215889A1
· Simard et al.
· 2003
[cited by applicant]
US 20040259877A1
· Muto et al.
· 2004
[cited by applicant]
US 20050085734A1
· Tehrani et al.
· 2005
[cited by applicant]
US 20050182012A1
· McEvoy et al.
· 2005
[cited by applicant]
US 20050187300A1
· Bajji et al.
· 2005
[cited by applicant]
US 20060014811A1
· Muto et al.
· 2006
[cited by applicant]
US 20060019958A1
· Jacobson et al.
· 2006
[cited by applicant]
US 20060035944A1
· Muto et al.
· 2006
[cited by applicant]
US 20060094718A1
· Muto et al.
· 2006
[cited by applicant]
US 20060100257A1
· Muto et al.
· 2006
[cited by applicant]
US 20060111409A1
· Muto et al.
· 2006
[cited by applicant]
US 20060167110A1
· Blume et al.
· 2006
[cited by applicant]
US 20070254956A1
· Shudo et al.
· 2007
[cited by applicant]
US 20070281978A1
· Nakada et al.
· 2007
[cited by applicant]
US 20080125488A1
· Leverve et al.
· 2008
[cited by applicant]
US 20080171719A1
· Chatterton et al.
· 2008
[cited by applicant]
US 20080176822A1
· Chen
· 2008
[cited by applicant]
US 20080214486A1
· Chatterton et al.
· 2008
[cited by applicant]
US 20080221169A1
· Flynn et al.
· 2008
[cited by applicant]
US 20080234233A1
· Muto et al.
· 2008
[cited by applicant]
US 20090163545A1
· Goldfarb
· 2009
[cited by applicant]
US 20090239868A1
· Muto et al.
· 2009
[cited by applicant]
US 20090239919A1
· Wood et al.
· 2009
[cited by applicant]
US 20100016381A1
· Asakawa et al.
· 2010
[cited by applicant]
US 20100113770A1
· Muto et al.
· 2010
[cited by applicant]
US 20100125090A1
· Hadida Ruah et al.
· 2010
[cited by applicant]
US 20100184856A1
· Lau et al.
· 2010
[cited by applicant]
US 20100190796A1
· Verkman et al.
· 2010
[cited by applicant]
US 20100274051A1
· Muto et al.
· 2010
[cited by applicant]
US 20110052678A1
· Shantha et al.
· 2011
[cited by applicant]
US 20110172195A1
· Flynn et al.
· 2011
[cited by applicant]
US 20120010178A1
· Rubin et al.
· 2012
[cited by applicant]
US 20120039805A1
· Lisanti et al.
· 2012
[cited by applicant]
US 20120183600A1
· Chen
· 2012
[cited by applicant]
US 20120196875A1
· Bouyssou et al.
· 2012
[cited by applicant]
US 20120238623A1
· Chandraratna et al.
· 2012
[cited by applicant]
US 20120245094A1
· Jacobsen et al.
· 2012
[cited by applicant]
US 20120282591A1
· Thatte et al.
· 2012
[cited by applicant]
US 20150166589A1
· Anderson et al.
· 2015
[cited by applicant]
US 20150342967A1
· Pelletier et al.
· 2015
[cited by applicant]
US 20160264604A1
· Pelletier et al.
· 2016
[cited by applicant]
US 20160279155A1
· Pelletier et al.
· 2016
[cited by applicant]
US 20180042873A1
· Pelletier et al.
· 2018
[cited by applicant]
US 20230293556A1
· Qian et al.
· 2023
[cited by applicant]
CA 2108794C
· 2003
[cited by applicant]
EP 0338415A2
· 1989
[cited by applicant]
EP 1352650A1
· 2003
[cited by applicant]
EP 1510210A1
· 2005
[cited by applicant]
EP 1512397A1
· 2005
[cited by applicant]
EP 1514544A1
· 2005
[cited by applicant]
EP 1535609A1
· 2005
[cited by applicant]
EP 1555018A1
· 2005
[cited by applicant]
EP 1649852A1
· 2006
[cited by applicant]
EP 2201946A1
· 2010
[cited by applicant]
RU 2461375C1
· 2012
[cited by applicant]
WO WO9907382A1
· 1999
[cited by applicant]
WO WO0123399A1
· 2001
[cited by applicant]
WO WO0249632A1
· 2002
[cited by applicant]
WO WO2004006858A2
· 2004
[cited by applicant]
WO WO2006036278A2
· 2006
[cited by applicant]
WO WO2006074127A2
· 2006
[cited by applicant]
WO WO2007084464A2
· 2007
[cited by applicant]
WO WO2007143689A2
· 2007
[cited by applicant]
WO WO2008046014A1
· 2008
[cited by applicant]
WO WO2008052190A2
· 2008
[cited by applicant]
WO WO2008060705A2
· 2008
[cited by applicant]
WO WO2008089103A2
· 2008
[cited by applicant]
WO WO2008089212A1
· 2008
[cited by applicant]
WO WO2008098160A1
· 2008
[cited by applicant]
WO WO2008100636A2
· 2008
[cited by applicant]
WO WO2008133884A2
· 2008
[cited by applicant]
WO WO2009002832A2
· 2008
[cited by applicant]
WO WO2009006555A2
· 2009
[cited by applicant]
WO WO2009054439A1
· 2009
[cited by applicant]
WO WO2009073711A1
· 2009
[cited by applicant]
WO WO2009074809A1
· 2009
[cited by applicant]
WO WO2009097443A2
· 2009
[cited by applicant]
WO WO2009139925A1
· 2009
[cited by applicant]
WO WO2010033560A2
· 2010
[cited by applicant]
WO WO2010048273A2
· 2010
[cited by applicant]
WO WO2010101648A1
· 2010
[cited by applicant]
WO WO2011112791A1
· 2011
[cited by applicant]
WO WO2012012347A1
· 2012
[cited by applicant]
WO WO2012150857A1
· 2012
[cited by applicant]
WO WO2013152313A1
· 2013
[cited by applicant]
WO WO2013165606A1
· 2013
[cited by applicant]
WO WO2013169939A2
· 2013
[cited by applicant]
WO WO2015037659A1
· 2015
[cited by applicant]
WO WO2015069948A1
· 2015
[cited by applicant]
WO WO2015069961A1
· 2015
[cited by applicant]
WO WO2016077787A1
· 2016
[cited by applicant]
WO WO2016196113A1
· 2016
[cited by applicant]
WO WO2017062765A1
· 2017
[cited by applicant]
WO WO2017197371A1
· 2017
[cited by applicant]
WO WO2018023035A1
· 2018
[cited by applicant]
WO WO2022028459A1
· 2022
[cited by applicant]
U.S. Appl. No. 12/381,086, filed Mar. 6, 2009, Wood et al.
[cited by applicant]
U.S. Appl. No. 14/398,947, filed Nov. 4, 2014 (371(c) Date), Pelletier et al.
[cited by applicant]
U.S. Appl. No. 14/752,839, filed Jun. 27, 2015, Pelletier et al.
[cited by applicant]
U.S. Appl. No. 15/034,274, filed May 4, 2016 (371(c) Date), Pelletier et al.
[cited by applicant]
U.S. Appl. No. 15/034,543, filed May 4, 2016 (371(c) Date), Pelletier et al.
[cited by applicant]
U.S. Appl. No. 15/792,707, filed Oct. 24, 2017, Pelletier et al.
[cited by applicant]
U.S. Appl. No. 15/982,644, filed May 17, 2018, Pelletier et al.
[cited by applicant]
U.S. Appl. No. 16/296,663, filed Mar. 8, 2019, Pelletier et al.
[cited by applicant]
U.S. Appl. No. 16/301,079, filed May 12, 2017 (371(c) Date), Pelletier et al.
[cited by applicant]
U.S. Appl. No. 16/665,333, filed Oct. 28, 2019, Pelletier et al.
[cited by applicant]
Aeromics, Anti-Edema Therapy for Patients Affected by Disabling and Life-Threatening Severe Ischemic Stroke, 6 pages, retrieved on Jul. 10, 2019, from: https://www.aeromics.com/.
[cited by applicant]
Aeromics, “Aeromics Initiates Phase 1 Clinical Trial of CNS Edema Inhibitor AER-271 in Healthy Human Volunteers,” dated Jul. 9, 2018, 4 pages, retrieved on Jul. 10, 2019, from: https://www.aeromics.com/press-releases/ae…
[cited by applicant]
Aeromics, “Aeromics, Inc. Appoints Pharmaceutical and Biotech Veterans Mark Day, Ph.D. and Thomas Zindrick, J.D. to Its Board of Directors,” dated Aug. 16, 2018, 7 pages, retrieved on Jul. 10, 2019, from: https://www.ae…
[cited by applicant]
Alexander, J. et al., “Administration of the Soluble Complement Inhibitor, Crry-Ig, Reduces Inflammation and Aquaporin 4 Expression in Lupus Cerebritis,” Biochimica et Biophysica Acta, 2003, 1639, 169-176.
[cited by applicant]
Amiry-Moghaddam, M. et al., “Alpha-Syntrophin Deletion Removes the Perivascular But Not Endothelial Pool of Aquaporin-4 at the Blood-Brain Barrier and Delays the Development of Brain Edema in an Experimental Model of Ac…
[cited by applicant]
Amiry-Moghaddam, M. et al. “Anchoring of Aquaporin-4 in Brain: Molecular Mechanisms and Implications for the Physiology and Pathophysiology of Water Transport,” Neuroscience, 2004, 129, 999-1010.
[cited by applicant]
Aoki, K. et al., “Enhanced Expression of Aquaporin 4 in Human Brain with Infarction,” Acta Neuropathologica, 2003, 106, 121-124.
[cited by applicant]
Aoki-Yoshino, K. et al., “Enhanced Expression of Aquaporin 4 in Human Brain with Inflammatory Diseases,” Acta Neuropathologica, 2005, 110, 281-288.
[cited by applicant]
Ayasoufi, K. et al., “Aquaporin 4 Blockade Improves Survival of Murine Heart Allografts Subjected to Prolonged Cold Ischemia,” American Journal of Transplantation, 2018, 18, 1238-1246.
[cited by applicant]
Baheti, A. et al., “Excipients Used in Lyophilization of Small Molecules,” Journal of Excipients and Food Chemicals, 2010, 1 (1), 41-54.
[cited by applicant]
Banamine (Flunixin Meglumine), retrieved from https://web.archive.org/web/20110711140225/http://www.banamine.com/research/FlunixinMeglumine.asp, 1 page, face of article states: Jul. 11, 2011.
[cited by applicant]
Bao, W. et al., “Selective mGluR5 Receptor Antagonist or Agonist Provides Neuroprotection in a Rat Model of Focal Cerebral Ischemia,” Brain Research, 2001, 922, 173-179.
[cited by applicant]
Bardutzky, J. et al., “Antiedema Therapy in Ischemic Stroke,” Stroke, 2007, 38, 3084-3094.
[cited by applicant]
Beeton, C. et al., “Induction and Monitoring of Active Delayed Type Hypersensitivity (DTH) in Rats,” JoVE. 6. http://www.jove.com/index/Details.stp?ID=237, doi:10.3791/237, 2007, 2 pages.
[cited by applicant]
Benga, O. et al., “Brain Water Channel Proteins in Health and Disease,” Molecular Aspects of Medicine, 2012, 33, 562-578.
[cited by applicant]
Bereczki, D. et al., “Cochrane Report: A Systematic Review of Mannitol Therapy for Acute Ischemic Stroke and Cerebral Parenchymal Hemorrhage,” Stroke, 2000, 31, 2719-2722.
[cited by applicant]
Berge, S. et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, 1977, 66 (1), 1-19.
[cited by applicant]
Bhattacharyya, S. et al., “Specific Effects of BCL10 Serine Mutations on Phosphorylations in Canonical and Noncanonical Pathways of NF-κB Activation Following Carrageenan,” The American Journal of Physiology, Gastrointe…
[cited by applicant]
Binder, D. et al., “Increased Seizure Threshold in Mice Lacking Aquaporin-4 Water Channels,” NeuroReport, 2004, 15 (2), 259-262.
[cited by applicant]
Binder, D. et al., “Increased Seizure Duration and Slowed Potassium Kinetics in Mice Lacking Aquaporin-4 Water Channels,” GLIA, 2006, 53, 631-636.
[cited by applicant]
Binder, D. et al., “Aquaporin-4 and Epilepsy,” GLIA, 2012, 60, 1203-1214.
[cited by applicant]
Bloch, O. et al., “Aquaporin-4 Gene Deletion in Mice Increases Focal Edema Associated with Staphylococcal Brain Abscess,” Journal of Neurochemistry, 2005, 95, 254-262.
[cited by applicant]
Brown, L. et al., “In Vitro and In Vivo Hydrolysis of Salicylanilide N-Methylcarbamate and 4-Biphenylyl N-Methylcarbamate,” Journal of Pharmaceutical Sciences, 1972, 61 (6), 858-860.
[cited by applicant]
Caraci, F. et al., “Metabotropic Glutamate Receptors in Neurodegeneration/Neuroprotection: Still a Hot Topic?,” Neurochemistry International, 2012, 61, 559-565.
[cited by applicant]
Cernak, I., “Animal Models of Head Trauma,” NeuroRx, 2005, 2 (3), 410-422.
[cited by applicant]
Chen, C. et al., “Animal Models of Nervous System Diseases,” Jilin Science and Technology Press, 2007, pp. 252-254.
[cited by applicant]
Chiamulera, C. et al., “Activation of Metabotropic Receptors has a Neuroprotective Effect in a Rodent Model of Focal Ischaemia,” European Journal of Pharmacology, 1992, 216, 335-336.
[cited by applicant]
Cooper, G. et al., “Transport of Volatile Solutes Through AQP1,” Journal of Physiology, 2002, 542.1, 17-29.
[cited by applicant]
Crash Trial, “Effect of Intravenous Corticosteroids on Death within 14 Days in 10008 Adults with Clinically Significant Head Injury (MRC Crash Trial): Randomised Placebo Controlled Trial,” Lancet, 2004, 364, 1321-1328.
[cited by applicant]
Da, T. et al., “Aquaporin-4 Gene Disruption in Mice Protects Against Impaired Retinal Function and Cell Death after Ischemia,” Investigative Ophthalmology & Visual Science, 2004, 45 (12), 4477-4483.
[cited by applicant]
Dearden, N. et al., “Effect of High-Dose Dexamethasone on Outcome from Severe Head Injury,” Journal of Neurosurgery, 1986, 64, 81-88.
[cited by applicant]
Di Renzo, G. et al., “Why have Ionotropic and Metabotropic Glutamate Antagonists Failed in Stroke Therapy?,” in New Strategies in Stroke Intervention, L. Annunziato, Ed., Humana Press, 2009, pp. 13-25.
[cited by applicant]
Dibas, A. et al., “Changes in Ocular Aquaporin-4 (AQP4) Expression Following Retinal Injury,” Molecular Vision, 2008, 14, 1770-1783.
[cited by applicant]
Ding, F., Neurobiology, Science Press, 2007, pp. 421-423.
[cited by applicant]
Ding, T. et al., “Knockdown a Water Channel Protein, Aquaporin-4, Induced Glioblastoma Cell Apoptosis,” PLoS ONE, 2013, 8 (8), e66751, 9 pages, doi:10.1371/journal.pone.0066751.
[cited by applicant]
Dixon, C. et al., “A Controlled Cortical Impact Model of Traumatic Brain Injury in the Rat,” Journal of Neuroscience Methods, 1991, 39, 253-262.
[cited by applicant]
Dudek, F. et al., “Regulation of Brain Water: Is there a Role for Aquaporins in Epilepsy?,” Epilepsy Currents, 2005, 5 (3), 104-106, retrieved on Jul. 22, 2015, from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1198631/.
[cited by applicant]
Eid, T. et al., “Loss of Perivascular Aquaporin 4 May Underlie Deficient Water and K
[cited by applicant]
Eisenberg, H. et al., “High-Dose Barbiturate Control of Elevated Intracranial Pressure in Patients with Severe Head Injury,” Journal of Neurosurgery, 1988, 69, 15-23.
[cited by applicant]
Elati, C. et al., “Novel Synthesis of Fosphenytoin: Anti-Convulsant Prodrug,” Synthetic Communications, 2008, 38 (17), 2950-2957.
[cited by applicant]
Engel, O. et al., “Modeling Stroke in Mice—Middle Cerebral Artery Occlusion with the Filament Model,” Journal of Visualized Experiments, 2011, 47, e2423, 5 pages, doi:10.3791/2423.
[cited by applicant]
Esteva-Font, C. et al., “Experimental Evaluation of Proposed Small-Molecule Inhibitors of Water Channel Aquaporin-1,” Molecular Pharmacology, 2016, 89, 686-693.
[cited by applicant]
Farinas, J. et al., “Plasma Membrane Water Permeability of Cultured Cells and Epithelia Measured by Light Microscopy with Spatial Filtering,” The Journal of General Physiology, 1997, 110, 283-296.
[cited by applicant]
Farr, G. et al., “Aquaporin-4 Inhibitor AER-270 and Its Prodrug AER-271 Reduce Cerebral Edema and Improve Outcomes in Two Models of CNS Injury,” Abstract M1905, Annals of Neurology, 2014, 76 (Supplement 18), S126-S127.
[cited by applicant]
Farr, G. et al., “Phenylbenzamide Derivatives AER-270/271 Inhibit Aquaporin-4 Reducing Cerebral Edema and Improving Outcome in Two Models of CNS Injury,” Poster presented at 2014 American Neurological Association Annual…
[cited by applicant]
Farr, G. et al., “Functionalized Phenylbenzamides Inhibit Aquaporin-4 Reducing Cerebral Edema and Improving Outcome in Two Models of CNS Injury,” Neuroscience, 2019, accepted manuscript, https://doi.org/10.1016/j.neuros…
[cited by applicant]
Fei, Z. et al., “Metabotropic Glutamate Receptor Antagonists and Agonists: Potential Neuroprotectors in Diffuse Brain Injury,” Journal of Clinical Neuroscience, 2006, 13, 1023-1027.
[cited by applicant]
Fischer, U. et al., “The Antioxidant N-Acetylcysteine Preserves Myocardial Function and Diminishes Oxidative Stress After Cardioplegic Arrest,” The Journal of Thoracic and Cardiovascular Surgery, 2003, 126 (5), 1483-148…
[cited by applicant]
Fomovska, A. et al., “Salicylanilide Inhibitors of
[cited by applicant]
Frigeri, A. et al., “Localization of MIWC and GLIP Water Channel Homologs in Neuromuscular, Epithelial and Glandular Tissues,” Journal of Cell Science, 1995, 108, 2993-3002.
[cited by applicant]
Frigeri, A. et al., “Immunolocalization of the Mercurial-Insensitive Water Channel and Glycerol Intrinsic Protein in Epithelial Cell Plasma Membranes,” Proceedings of the National Academy of Sciences, 1995, 92, 4328-433…
[cited by applicant]
Gerber, J. et al., “Mechanisms of Injury in Bacterial Meningitis,” Current Opinion in Neurology, 2010, 23, 312-318.
[cited by applicant]
Gomez-Cabrero, A. et al., “IMD-0354 Targets Breast Cancer Stem Cells: A Novel Approach for an Adjuvant to Chemotherapy to Prevent Multidrug Resistance in a Murine Model,” PLoS One, 2013, 8 (8), e73607, 14 pages, doi:10.…
[cited by applicant]
Gotoh, O. et al., “Ischemic Brain Edema Following Occlusion of the Middle Cerebral Artery in the Rat. I: The Time Courses of the Brain Water, Sodium and Potassium Contents and Blood Brain Barrier Permeability to
[cited by applicant]
Gullans, S., “Control of Brain Volume During Hyperosmolar and Hypoosmolar Conditions,” Annual Review of Medicine, 1993, 44, 289-301.
[cited by applicant]
Gunnarson, E. et al., “Identification of a Molecular Target for Glutamate Regulation of Astrocyte Water Permeability,” Glia, 2008, 56, 587-596.
[cited by applicant]
Guo, Q. et al., “Progesterone Administration Modulates AQP4 Expression and Edema After Traumatic Brain Injury in Male Rats,” Experimental Neurology, 2006, 198, 469-478.
[cited by applicant]
Hall, G. et al., “Inhibitor-κB Kinase-β regulates LPS-Induced TNF-α Production in Cardiac Myocytes Through Modulation of NF-κB p65 Subunit Phosphorylation,” American Journal of Heart Physiology, Heart and Circulatory Ph…
[cited by applicant]
Himadri, P. et al., “Role of Oxidative Stress and Inflammation in Hypoxia-Induced Cerebral Edema: A Molecular Approach,” High Altitude Medicine & Biology, 2010, 11 (3), 231-244.
[cited by applicant]
Hiroaki, Y. et al., “Implications of the Aquaporin-4 Structure on Array Formation and Cell Adhesion,” Journal of Molecular Biology, 2006, 355, 628-639.
[cited by applicant]
Ho, J. et al., “Crystal Structure of Human Aquaporin 4 at 1.8 Å and Its Mechanism of Conductance,” Proceedings of the National Academy of Sciences, 2009, 106 (18), 7437-7442.
[cited by applicant]
Hsu, M. et al., “Potential Role of the Glial Water Channel Aquaporin-4 in Epilepsy,” Neuron Glia Biology, 2008, doi: 10.1017/S1740925X08000112, 11 pages.
[cited by applicant]
Huber, V. et al., “Identification of Arylsulfonamides as Aquaporin 4 Inhibitors,” Bioorganic & Medicinal Chemistry Letters, 2007, 17, 1270-1273.
[cited by applicant]
Huber, V. et al., “Identification of Aquaporin 4 Inhibitors Using in vitro and in silico Methods,” Bioorganic & Medicinal Chemistry, 2009, 17, 411-417.
[cited by applicant]
Huber, V. et al., “Inhibition of Aquaporin 4 by Antiepileptic Drugs,” Bioorganic & Medicinal Chemistry, 2009, 17, 418-424.
[cited by applicant]
Igarashi, H. et al., “Pretreatment with a Novel Aquaporin 4 Inhibitor, TGN-020, Significantly Reduces Ischemic Cerebral Edema,” Neurological Sciences, 2011, 32, 113-116.
[cited by applicant]
Ikeshima-Kataoka, H., “Neuroimmunological Implications of AQP4 in Astrocytes,” International Journal of Molecular Sciences, 2016, 17, 1306, 16 pages, doi:10.3390/ijms17081306.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2013/040194, Date of issuance of the report Nov. 11, 2014, 8 pages.
[cited by applicant]
International Search Report for International Application No. PCT/US2013/040194, Date of mailing Dec. 20, 2013, 5 pages.
[cited by applicant]
International Search Report for International Application No. PCT/US2014/064432, Date of mailing Apr. 13, 2015, 5 pages.
[cited by applicant]
International Search Report for International Application No. PCT/US2014/064441, Date of mailing Feb. 13, 2015, 4 pages.
[cited by applicant]
International Search Report for International Application No. PCT/US2014/064447, Date of mailing Apr. 6, 2015, 5 pages.
[cited by applicant]
International Search Report for International Application No. PCT/US2015/060731, Date of mailing Jan. 29, 2016, 4 pages.
[cited by applicant]
International Search Report for International Application No. PCT/US2017/032563, Date of mailing Aug. 24, 2017, 3 pages.
[cited by applicant]
Ito, J. et al., “Characterization of Edema by Diffusion-Weighted Imaging in Experimental Traumatic Brain Injury,” Journal of Neurosurgery, 1996, 84, 97-103.
[cited by applicant]
Jeyaseelan, K. et al., “Aquaporins: A Promising Target for Drug Development,” Expert Opinion on Therapeutic Targets, 2006, 10 (6), 889-909.
[cited by applicant]
Jung, J. et al., “Molecular Characterization of an Aquaporin cDNA from Brain: Candidate Osmoreceptor and Regulator of Water Balance,” Proceedings of the National Academy of Sciences, 1994, 91, 13052-13056.
[cited by applicant]
Jüttler, E. et al., “Clinical Review: Therapy for Refractory Intracranial Hypertension in Ischaemic Stroke,” Critical Care, 2007, 11, 231, 14 pages, doi:10.1186/cc6087.
[cited by applicant]
Kalita, J. et al., “Current Status of Osmotherapy in Intracerebral Hemorrhage,” Neurology India, 2003, 51 (1), 104-109.
[cited by applicant]
Kamegawa, A. et al., “Two-dimensional Crystal Structure of Aquaporin-4 Bound to the Inhibitor Acetazolamide,” Microscopy, 2016, 65 (2), 177-184.
[cited by applicant]
Kamon, J. et al., “A Novel IKKβ Inhibitor Stimulates Adiponectin Levels and Ameliorates Obesity-Linked Insulin Resistance,” Biochemical and Biophysical Research Communications, 2004, 323, 242-248.
[cited by applicant]
Katada, R. et al., “Greatly Improved Survival and Neuroprotection in Aquaporin-4-Knockout Mice Following Global Cerebral Ischemia,” The FASEB Journal, 2014, 28, 10 pages, face of article states: published online Nov. 1,…
[cited by applicant]
Kaufmann, A. et al., “Ischemic Core and Penumbra in Human Stroke,” Stroke, 1999, 30, 93-99.
[cited by applicant]
Ke, C. et al., “Heterogeneous Responses of Aquaporin-4 in Oedema Formation in a Replicated Severe Traumatic Brain Injury Model in Rats,” Neuroscience Letters, 2001, 301, 21-24.
[cited by applicant]
Kiening, K. et al., “Decreased Hemispheric Aquaporin-4 is Linked to Evolving Brain Edema Following Controlled Cortical Impact Injury in Rats,” Neuroscience Letters, 2002, 324, 105-108.
[cited by applicant]
Kirby, A. et al., “The Reactivity of Phosphate Esters. Monoester Hydrolysis,” Journal of the American Chemical Society, 1967, 89 (2), 415-423.
[cited by applicant]
Kochanek, P. et al., “Operation Brain Trauma Therapy: 2016 Update,” Military Medicine, 2018, 183, 303-312.
[cited by applicant]
Krave, U. et al., “Transient, Powerful Pressures are Generated in the Brain by a Rotational Acceleration Impulse to the Head,” European Journal of Neuroscience, 2005, 21, 2876-2882.
[cited by applicant]
Lea, P. et al., “Neuroprotective Activity of the mGluR5 Antagonists MPEP and MTEP Against Acute Excitotoxicity Differs and Does Not Reflect Actions at mGluR5 Receptors,” British Journal of Pharmacology, 2005, 145 (4), 5…
[cited by applicant]
Lee, D. et al., “Decreased Expression of the Glial Water Channel Aquaporin-4 in the Intrahippocampal Kainic Acid Model of Epileptogenesis,” Experimental Neurology, 2012, doi:10.1016/j.expneurol.2012.02.002, 10 pages.
[cited by applicant]
Lennikov, A. et al., “Amelioration of Endotoxin-induced Uveitis Treated with an IκB Kinase β Inhibitor in Rats,” Molecular Vision, 2012, 18, 2586-2597.
[cited by applicant]
Lennikov, A. et al., “Selective IKK2 Inhibitor IMD0354 Disrupts NF-κB Signaling to Suppress Corneal Inflammation and Angiogenesis,” Angiogenesis, 2018, 21, 267-285.
[cited by applicant]
Lennon, V. et al., “IgG Marker of Optic-Spinal Multiple Sclerosis Binds to the Aquaporin-4 Water Channel,” The Journal of Experimental Medicine, 2005, 202 (4), 473-477.
[cited by applicant]
Li, J. et al., “Synthesis and Biological Evaluation of a Water Soluble Phosphate Prodrug of 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone (3-AP),” Bioorganic & Medicinal Chemistry Letters, 1998, 8, 3159-3164.
[cited by applicant]
Li, L. et al., “Greatly Attenuated Experimental Autoimmune Encephalomyelitis in Aquaporin-4 Knockout Mice,” BMC Neuroscience, 2009, 10, 94, 5 pages, doi:10.1186/1471-2202-10-94.
[cited by applicant]
Li, L. et al., “Proinflammatory Role of Aquaporin-4 in Autoimmune Neuroinflammation,” The FASEB Journal, 2011, 25, 1556-1566.
[cited by applicant]
Li, Y-R. et al., “Study of the Inhibitory Effects on TNF-α-induced NF-κB Activation of IMD0354 Analogs,” Chemical Biology & Drug Design, 2017, 90, 1307-1311.
[cited by applicant]
Loane, D. et al., “Activation of Metabotropic Glutamate Receptor 5 Modulates Microglial Reactivity and Neurotoxicity by Inhibiting NADPH Oxidase,” The Journal of Biological Chemistry, 2009, 284 (23), 15629-15639.
[cited by applicant]
Longa, E. et al., “Reversible Middle Cerebral Artery Occlusion Without Craniectomy in Rats,” Stroke, 1989, 20, 84-91.
[cited by applicant]
Ma, T. et al., “Generation and Phenotype of a Transgenic Knockout Mouse Lacking the Mercurial-Insensitive Water Channel Aquaporin-4,” Journal of Clinical Investigation, 1997, 100 (5), 957-962.
[cited by applicant]
Maddahi, A. et al., “The Role of Tumor Necrosis Factor-α and TNF-α Receptors in Cerebral Arteries Following Cerebral Ischemia in Rat,” Journal of Neuroinflammation, 2011, 8:107, 13 pages, doi:10.1186/1742-2094-8-107.
[cited by applicant]
Manley, G. et al., “Aquaporin-4 Deletion in Mice Reduces Brain Edema After Acute Water Intoxication and Ischemic Stroke,” Nature Medicine, 2000, 6 (2), 159-163.
[cited by applicant]
Manley, G. et al., “New Insights into Water Transport and Edema in the Central Nervous System from Phenotype Analysis of Aquaporin-4 Null Mice,” Neuroscience, 2004, 129, 983-991.
[cited by applicant]
Marmarou, A. et al., “Traumatic Brain Edema in Diffuse and Focal Injury: Cellular or Vasogenic?,” Acta Neurochirurgica, 2006 [Supplement], 96, 24-29.
[cited by applicant]
Mehlhorn, U. et al., “Myocardial Fluid Balance,” European Journal of Cardio-throacic Surgery, 2001, 20, 1220-1230.
[cited by applicant]
Meli, E. et al., “Activation of mGlul but not mGlu5 Metabotropic Glutamate Receptors Contributes to Postischemic Neuronal Injury In Vitro and In Vivo,” Pharmacology, Biochemistry and Behavior, 2002, 73, 439-446.
[cited by applicant]
Migliati, E. et al., “Inhibition of Aquaporin-1 and Aquaporin-4 Water Permeability by a Derivative of the Loop Diuretic Bumetanide Acting at an Internal Pore-Occluding Binding Site,” Molecular Pharmacology, 2009, 76 (1)…
[cited by applicant]
Mola, M. et al., “Automated Cell-Based Assay for Screening of Aquaporin Inhibitors,” Analytical Chemistry, 2009, 81, 8219-8229.
[cited by applicant]
Mola, M. et al., “Automated Cell-Based Assay for Screening of Aquaporin Inhibitors,” Author Manuscript, available in PMC 2010, 24 pages, face of article states: Published in final edited form as:
[cited by applicant]
Monai, H. et al., “Adrenergic Receptor Antagonism Induces Neuroprotection and Facilitates Recovery from Acute Ischemic Stroke,” Proceedings of the National Academy of Sciences, 2019, 116 (22), 11010-11019.
[cited by applicant]
Morimoto, Y. et al., “Acute Brain Swelling After Out-of-Hospital Cardiac Arrest: Pathogenesis and Outcome,” Critical Care Medicine, 1993, 21 (1), 104-110.
[cited by applicant]
Neely, J. et al., “Syntrophin-Dependent Expression and Localization of Aquaporin-4 Water Channel Protein,” Proceedings of the National Academy of Sciences, 2001, 98 (24), 14108-14113.
[cited by applicant]
Nicosia, M. et al., “Aquaporin 4 Blockade Alters T Cell Trafficking Through a Novel Mechanism of SIPR1 Regulation,” The Journal of Immunology, 2018, 200 (1 Supplement) 55.33, abstract only, 4 pages, retrieved on Oct. 10…
[cited by applicant]
Nicosia, M. et al., “Aquaporin 4 Inhibition Alters Chemokine Receptor Expression and T Cell Trafficking,” Scientific Reports, 2019, 9:7417, 11 pages, https://doi.org/10.1038/s41598-019-43884-2.
[cited by applicant]
Nishikawa, S. et al., “A Molecular Targeting Against Nuclear Factor-κB, as a Chemotherapeutic Approach for Human Malignant Mesothelioma,” Cancer Medicine, 2014, 3 (2), 416-425.
[cited by applicant]
Nordqvist, C. “Everything You Need to Know About Infections,” Medical News Today, face of article states: Last updated Tue Aug. 22, 2017, 11 pages, retrieved on Nov. 26, 2018, from: https://www.medicalnewstoday.com/arti…
[cited by applicant]
Ogawa, M. et al., “The Mechanism of Anti-Inflammatory Effects of Prostaglandin E
[cited by applicant]
Onai, Y. et al., “Inhibition of IκB Phosphorylation in Cardiomyoctyes Attenuates Myocardial Ischemia/Reperfusion Injury,” Cardiovascular Research, 2004, 63, 51-59.
[cited by applicant]
Onai, Y. et al., “Inhibition of NF-κB Improves Left Ventricular Remodeling and Cardiac Dysfunction after Myocardial Infarction,” American Journal of Heart Physiology, Heart and Circulatory Physiology, 2007, 292, H530-H5…
[cited by applicant]
Pallan, T. et al., “Glyburide in Treating Malignant Cerebral Edema. Blocking Sulfonyl Urea One (SUR1) Receptors,” Journal of Vascular and Interventional Neurology, 2014, 22-24.
[cited by applicant]
Papadopoulos, M. et al., “Aquaporin-4 Facilitates Reabsorption of Excess Fluid in Vasogenic Brain Edema,” The FASEB Journal, published online Jun. 18, 2004, doi: 10.1096/fj.04-1723jfe, 18 pages.
[cited by applicant]
Papadopoulos, M. et al., “Aquaporin-4 Facilitates Reabsorption of Excess Fluid in Vasogenic Brain Edema,” The FASEB Journal, 2004, 18, 1291-1293.
[cited by applicant]
Papadopoulos, M. et al., “Aquaporin-4 Gene Disruption in Mice Reduces Brain Swelling and Mortality in Pneumococcal Meningitis,” The Journal of Biological Chemistry, 2005, 280 (14), 13906-13912.
[cited by applicant]
Papadopoulos, M. et al., “Potential Utility of Aquaporin Modulators for Therapy of Brain Disorders,” NIH Public Access, Author Manuscript, available in PMC 2013, 17 pages, face of article states: Published in final edit…
[cited by applicant]
Papadopoulos, M. et al., “Aquaporin Water Channels in the Nervous System,” NIH Public Access, Author Manuscript, available in PMC 2014, 28 pages, face of article states: Published in final edited form as:
[cited by applicant]
Pippione, A. et al., “4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: A Novel Inhibitor of the Canonical NF-κB Cascade,” Medicinal Chemistry Communications, 2017, 8, 1850-1855.
[cited by applicant]
Prescott, J. et al., “Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors,” Cells, 2018, 7, 115, 34 pages, doi:10.3390/cells7090115.
[cited by applicant]
Quick, A. et al., “Pregnancy-Induced Up-Regulation of Aquaporin-4 Protein in Brain and Its Role in Eclampsia,” The FASEB Journal, 2005, 19, 170-175.
[cited by applicant]
Rabinstein, A., “Treatment of Cerebral Edema,” The Neurologist, 2006, 12 (2), 59-73.
[cited by applicant]
Rao, K. et al., “Marked Potentiation of Cell Swelling by Cytokines in Ammonia-Sensitized Cultured Astrocytes,” Journal of Neuroinflammation, 2010, 7 (66), 8 pages.
[cited by applicant]
Raslan, A. et al., “Medical Management of Cerebral Edema,” Neurosurgical Focus, 2007, 22 (5), E12, 12 pages.
[cited by applicant]
Raslan, A. et al., “Medical Management of Cerebral Edema,” retrieved on Jan. 2, 2015, from http://www.medscape.com/viewarticle559004_6, 17 pages, face of article states: Neurosurgery Focus, 2007, 22 (5), E12.
[cited by applicant]
Restrepo, D. et al., “Essential Activation of Na
[cited by applicant]
Restrepo, L. et al., “Osmotherapy: A Call to Arms,” Stroke, 2001, 32, 811-812.
[cited by applicant]
Rutkovskiy, A. et al., “Aquaporin-4 in the Heart: Expression, Regulation and Functional Role in Ischemia,” Basic Research in Cardiology, 2012, 107:280, 13 pages, doi: 10.1007/s00395-012-0280-6.
[cited by applicant]
Saadoun, S. et al., “Involvement of Aquaporin-4 in Astroglial Cell Migration and Glial Scar Formation,” Journal of Cell Science, 2005, 118, 5691-5698.
[cited by applicant]
Saadoun, S. et al., “Greatly Improved Neurological Outcome After Spinal Cord Compression Injury in AQP4-Deficient Mice,” Brain, 2008, 131, 1087-1098.
[cited by applicant]
Saadoun, S. et al., “AQP4 Gene Deletion in Mice Does Not Alter Blood-Brain Barrier Integrity or Brain Morphology,” Neuroscience, 2009, 161, 764-772.
[cited by applicant]
Saadoun, S. et al., “Aquaporin-4 in Brain and Spinal Cord Oedema,” Neuroscience, 2010, 168, 1036-1046.
[cited by applicant]
Sandhu, H. et al., “Upregulation of Contractile Endothelin Type B Receptors by Lipid-soluble Cigarette Smoking Particles in Rat Cerebral Arteries via Activation of MAPK,” Toxicology and Applied Pharmacology, 2010, 249, …
[cited by applicant]
Schwartz, M. et al., “The University of Toronto Head Injury Treatment Study: A Prospective, Randomized Comparison of Pentobarbital and Mannitol,” The Canadian Journal of Neurological Sciences, 1984, 11, 434-440.
[cited by applicant]
Second Office Action issued in Chinese Patent Application No. 201380033198.7 dated Dec. 13, 2016, and English-language translation, 13 pages (8 pages Second Office Action, 5 pages translation).
[cited by applicant]
Sepramaniam, S. et al. “MicroRNA 320a Functions as a Novel Endogenous Modulator of Aquaporins 1 and 4 as Well as a Potential Therapeutic Target in Cerebral Ischemia,” The Journal of Biological Chemistry, 2010, 285 (38),…
[cited by applicant]
Silberstein, C. et al., “Membrane Organization and Function of M1 and M23 Isoforms of Aquaporin-4 in Epithelial Cells,” American Journal of Physiology, Renal Physiology, 2004, 287, F501-F511.
[cited by applicant]
Slater, J. et al., “Discriminating Between Preservation and Reperfusion Injury in Human Cardiac Allografts Using Heart Weight and Left Ventricular Mass,” retrieved on Jul. 23, 2015, from https://circ.ahajournals.org/con…
[cited by applicant]
Slivka, A. et al., “High Dose Methylprednisolone Treatment in Experimental Focal Cerebral Ischemia,” Experimental Neurology, 2001, 167, 166-172.
[cited by applicant]
Sodium Phosphate, Cold Spring Harbor Protocols, doi:10.1101/pdb.rec8303, face of document states: copyright 2006, 1 page, retrieved Dec. 9, 2019 from: http://cshprotocols.cshlp.org/content/2006/1/pdb.rec8303.full?text_o…
[cited by applicant]
Solenov, E. et al., “Sevenfold-Reduced Osmotic Water Permeability in Primary Astrocyte Cultures from AQP-4-Deficient Mice, Measured by a Fluorescence Quenching Method,” American Journal of Physiology, Cell Physiology, 2…
[cited by applicant]
Steiner, T. et al., “Treatment Options for Large Hemispheric Stroke,” Neurology, 2001, 57 (Supplement 2), S61-68.
[cited by applicant]
Stella, V. et al., Eds., Biotechnology: Pharmaceutical Aspects; Prodrugs: Challenges and Rewards, Part 2, Springer, New York, New York, 2007, p. 161.
[cited by applicant]
Stokum, J. et al., “Molecular Pathophysiology of Cerebral Edema,” Journal of Cerebral Blood Flow & Metabolism, 2016, 36 (3), 513-538.
[cited by applicant]
Stroop, R. et al., “Magnetic Resonance Imaging Studies with Cluster Algorithm for Characterization of Brain Edema after Controlled Cortical Impact Injury (CCII),” Acta Neurochirurgica, 1998 [Supplement], 71, 303-305.
[cited by applicant]
Su, C. et al., “Endogenous Memory CD8 T Cells Directly Mediate Cardiac Allograft Rejection,” American Journal of Transplantation, 2014, 14, 568-579.
[cited by applicant]
Sui, H. et al., “Structural Basis of Water-Specific Transport Through the AQP1 Water Channel,” Nature, 2001, 414 (20/27), 872-878.
[cited by applicant]
Sun, M. et al., “Regulation of Aquaporin-4 in a Traumatic Brain Injury Model in Rats,” Journal of Neurosurgery, 2003, 98, 565-569.
[cited by applicant]
Suzuki, J. et al., “Novel IκB Kinase Inhibitors for Treatment of Nuclear Factor-κB-related Diseases,” Expert Opinion on Investigational Drugs, 2011, 20 (3), 395-405.
[cited by applicant]
Szabó, G. et al., “Systolic and Diastolic Properties and Myocardial Blood Flow in the Heterotopically Transplanted Rat Heart during Acute Cardiac Rejection,” World Journal of Surgery, 2001, 25, 545-552.
[cited by applicant]
Tait, M. et al. “Increased Brain Edema in AQP4-Null Mice in an Experimental Model of Subarachnoid Hemorrhage,” Neuroscience, 2010, 167, 60-67.
[cited by applicant]
Tajkhorshid, E. et al., “Control of the Selectivity of the Aquaporin Water Channel Family by Global Orientational Tuning,” Science, 2002, 296, 525-530.
[cited by applicant]
Tanaka, A. et al., “Topical Application with a New NF-κB Inhibitor Improves Atopic Dermatitis in NC/NgaTnd Mice,” Journal of Investigative Dermatology, 2007, 127, 855-863.
[cited by applicant]
Tang, Z. et al., “Structure-Activity Relationship of Niclosamide Derivatives,” Anticancer Research, 2017, 37, 2839-2843.
[cited by applicant]
Taniguchi, M. et al., “Induction of Aquaporin-4 Water Channel mRNA After Focal Cerebral Ischemia in Rat,” Molecular Brain Research, 2000, 78, 131-137.
[cited by applicant]
Tanimura, Y. et al., “Acetazolamide Reversibly Inhibits Water Conduction by Aquaporin-4,” Journal of Structural Biology, 2009, 166, 16-21.
[cited by applicant]
Townsend, R. et al., “A Highly Selective Inhibitor of IκB Kinase, BMS-345541, Augments Graft Survival Mediated by Suboptimal Immunosupression in a Murine Model of Cardiac Graft Rejection,” Transplantation, 2004, 77 (7),…
[cited by applicant]
Unterberg, A. et al., “Characterisation of Brain Edema Following ‘Controlled Cortical Impact Injury’ in Rats,” Acta Neurochirurgica, 1997 [Supplement], 70, 106-108.
[cited by applicant]
Unterberg, A. et al., “Edema and Brain Trauma,” Neuroscience, 2004, 129, 1021-1029.
[cited by applicant]
Van Hoek, A. et al., “Freeze-Fracture Analysis of Plasma Membranes of CHO Cells Stably Expressing Aquaporins 1-5,” The Journal of Membrane Biology, 1998, 165, 243-254.
[cited by applicant]
Verkman, A. et al., “Three Distinct Roles of Aquaporin-4 in Brain Function Revealed by Knockout Mice,” Biochmica et Biophysica Acta, 2006, doi: 10.1016/j.bbamem.2006.02.018, 9 pages.
[cited by applicant]
Verkman, A., “Aquaporins at a Glance,” Journal of Cell Science, 2011, 124, 2107-2112.
[cited by applicant]
Verkman, A. et al., “Aquaporin-4: Orthogonal Array Assembly, CNS Functions, and Role in Neuromyelitis Optica,” Author Manuscript, available in PMC 2013, 16 pages, face of article states: Published in final edited form a…
[cited by applicant]
Verkman, A., “Aquaporins in Clinical Medicine,” NIH Public Access, Author Manuscript, available in PMC 2013, 16 pages, face of article states: Published in final edited form as:
[cited by applicant]
Verkman, A. et al., “Aquaporins: Important But Elusive Drug Targets,” Nature Reviews Drug Discovery, published online 2014, 19 pages, doi:10.1038/nrd4426.
[cited by applicant]
Verkman, A. et al., “The Aquaporin-4 Water Channel as a Potential Drug Target in Neurological Disorders,” HHS Public Access, Author Manuscript, available in PMC 2019, 21 pages, face of article states: Published in final…
[cited by applicant]
Vizuete, M. et al., “Differential Upregulation of Aquaporin-4 mRNA Expression in Reactive Astrocytes After Brain Injury: Potential Role in Brain Edema,” Neurobiology of Disease, 1999, 6, 245-258.
[cited by applicant]
Wakatsuki, S. et al., “A Novel IKK Inhibitor Suppresses Heart Failure and Chronic Remodeling After Myocardial Ischemia via MMP Alteration,” Expert Opinion on Therapeutic Targets, 2008, 12 (12), 1469-1476.
[cited by applicant]
Wallisch, J. et al., “Effect of the Novel Aquaporin-4 Antagonist AER-271 in Combined TBI Plus Hemorrhagic Shock in Mice,” Critical Care Medicine, 2015, 43 (12, Supplement), Abstract 23.
[cited by applicant]
Wallisch, J. et al., “Aquaporin-4 Inhibitor AER-271 Blocks Early Cerebral Edema in Pediatric Rat Asphyxial Cardiac Arrest,” Critical Care Medicine, 2016, 44 (12, Supplement), Abstract 718.
[cited by applicant]
Wallisch, J. et al., “Evaluation of AER-271 in the Controlled Cortical Impact Model of Traumatic Brain Injury: An OBTT Consortium Study,” Journal of Neurotrauma, 2016, 33, A-61, Abstract PSA-137.
[cited by applicant]
Wallisch, J. et al., “Aquaporin-4 Inhibitor AER-271 Blocks Edema and Improves Outcome in Pediatric Rat Cardiac Arrest,” Critical Care Medicine, 2017, 46 (1, Supplement), Abstract 49.
[cited by applicant]
Wallisch, J. et al., “The Aquaporin-4 Inhibitor AER-271 Blocks Acute Cerebral Edema and Improves Early Outcome in a Pediatric Model of Asphyxial Cardiac Arrest,” Pediatric Research, 2018, https://doi.org/10.1038/s41390-…
[cited by applicant]
Wang, F. et al., “Aquaporins as Potential Drug Targets,” Acta Pharmacologica Sinica, 2006, 27 (4), 395-401.
[cited by applicant]
Wang, J-W. et al., “Activation of Metabotropic Glutamate Receptor 5 Reduces the Secondary Brain Injury After Traumatic Brain Injury in Rats,” Biochemical and Biophysical Research Communications, 2013, 430, 1016-1021.
[cited by applicant]
Wang, X. et al., “Pre-Ischemic Treadmill Training Alleviates Brain Damage via GLT-1-Mediated Signal Pathway After Ischemic Stroke in Rats,” Neuroscience, 2014, 274, 393-402.
[cited by applicant]
Wick, W. et al., “Brain Edema in Neurooncology: Radiological Assessment and Management,” Onkologie, 2004, 27, 261-266.
[cited by applicant]
Wilson, M. et al., “The Cerebral Effects of Ascent to High Altitudes,” Lancet Neurology, 2009, 8, 175-191.
[cited by applicant]
Wong, L. et al., “Vasoporessin V2 Receptor Antagonists,” Cardiovascular Research, 2001, 51, 391-402.
[cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/US2014/064432, Date of mailing Apr. 13, 2015, 7 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/US2014/064441, Date of mailing Feb. 13, 2015, 8 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/US2014/064447, Date of mailing Apr. 6, 2015, 6 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/US2015/060731, Date of mailing Jan. 29, 2016, 8 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/US2017/032563, Date of mailing Aug. 24, 2017, 5 pages.
[cited by applicant]
Yang, B. et al., “The Mercurial Insensitive Water Channel (AQP-4) Forms Orthogonal Arrays in Stably Transfected Chinese Hamster Ovary Cells,” The Journal of Biological Chemistry, 1996, 271 (9), 4577-4580.
[cited by applicant]
Yang, B. et al., “Lack of Aquaporin-4 Water Transport Inhibition by Antiepileptics and Arylsulfonamides,” Bioorganic & Medicinal Chemistry, 2008, 16, 7489-7493.
[cited by applicant]
Yang, N. et al., “Effect of (S)-4C3HPG on Brain Damage in the Acute Stage of Moderate Traumatic Brain Injury Model of Mice and Underlying Mechanism,” Acta Physiologica Sinica, 2010, 62 (6), 555-559.
[cited by applicant]
Yao, X. et al., “Mildly Reduced Brain Swelling and Improved Neurological Outcome in Aquaporin-4 Knockout Mice following Controlled Cortical Impact Brain Injury,” Journal of Neurotrauma, 2015, 32, 1458-1464.
[cited by applicant]
Young, E., Chapter 9 entitled “IKKβ as a Therapeutic Intervention Point for Diseases Related to Inflammation,” pp. 255-296, in Anti-Inflammatory Drug Discovery, Levin, J. et al., Eds., Royal Society of Chemistry, 2012.
[cited by applicant]
Zador, Z et al., “Aquaporins: Role in Cerebral Edema and Brain Water Balance,” Progress in Brain Research, 2007, 161, Chapter 12, 185-194.
[cited by applicant]
Zeidel, M. et al., “Ultrastructure, Pharmacologic Inhibition, and Transport Selectivity of Aquaporin Channel-Forming Integral Protein in Proteoliposomes,” Biochemistry, 1994, 33, 1606-1615.
[cited by applicant]
Zelenina, M. et al., “Water Permeability of Aquaporin-4 is Decreased by Protein Kinase C and Dopamine,” American Journal of Physiology, Renal Physiology, 2002, 283, F309-F318.
[cited by applicant]
Zhang, D. et al., “Aquaporin Deletion in Mice Reduces Intraocular Pressure and Aqueous Fluid Production,” The Journal of General Physiology, 2002, 119, 561-569.
[cited by applicant]
Zhang, F. et al., “The Effect of Treadmill Training Pre-Exercise on Glutamate Receptor Expression in Rats After Cerebral Ischemia,” International Journal of Molecular Sciences, 2010, 11, 2658-2669.
[cited by applicant]
Zhang, Z-Y. et al., “Activation of mGluR5 Attenuates Microglial Activation and Neuronal Apoptosis in Early Brain Injury After Experimental Subarachnoid Hemorrhage in Rats,” Neurochemical Research, 2015, 40, 1121-1132.
[cited by applicant]
Zhao, F. et al., “Aquaporin-4 Deletion Ameliorates Hypoglycemia-induced BBB Permeability by Inhibiting Inflammatory Responses,” Journal of Neuroinflammation, 2018, 15:157, 13 pages, https://doi.org/10.1186/s12974-018-12…
[cited by applicant]
Requirement for Restriction/Election dated Aug. 13, 2015, issued in U.S. Appl. No. 14/398,947, 10 pages.
[cited by applicant]
Non-Final Office Action dated Dec. 18, 2015, issued in U.S. Appl. No. 14/398,947, 31 pages.
[cited by applicant]
Final Office Action dated Sep. 20, 2016, issued in U.S. Appl. No. 14/398,947, 41 pages.
[cited by applicant]
Advisory Action dated Dec. 16, 2016, issued in U.S. Appl. No. 14/398,947, 3 pages.
[cited by applicant]
Non-Final Office Action dated Aug. 16, 2017, issued in U.S. Appl. No. 14/398,947, 24 pages.
[cited by applicant]
Notice of Allowance issued Feb. 2, 2018, in U.S. Appl. No. 14/398,947, 10 pages.
[cited by applicant]
Notice of Allowability and Examiner-Initiated Interview Summary issued Feb. 15, 2018, in U.S. Appl. No. 14/398,947, 7 pages.
[cited by applicant]
Requirement for Restriction/Election dated Sep. 22, 2015, issued in U.S. Appl. No. 14/752,839, 6 pages.
[cited by applicant]
Non-Final Office Action dated Mar. 8, 2016, issued in U.S. Appl. No. 14/752,839, 23 pages.
[cited by applicant]
Final Office Action dated Aug. 30, 2016, issued in U.S. Appl. No. 14/752,839, 17 pages.
[cited by applicant]
Notice of Allowance mailed Oct. 7, 2016, in U.S. Appl. No. 14/752,839, 10 pages.
[cited by applicant]
Notice of Allowance mailed Jul. 19, 2017, issued in U.S. Appl. No. 15/034,274, 9 pages.
[cited by applicant]
U.S. Appl. No. 18/819,236, filed Aug. 29, 2024, McGuirk et al.
[cited by applicant]
U.S. Appl. No. 17/304,201, filed Jun. 16, 2021, Pelletier et al.
[cited by applicant]
U.S. Appl. No. 18/351,472, filed Jul. 12, 2023, McGuirk et al.
[cited by applicant]
U.S. Appl. No. 18/537,093, filed Dec. 12, 2023, Pelletier et al.
[cited by applicant]
U.S. Appl. No. 19/035,433, filed Jan. 23, 2025, Pelletier et al.
[cited by applicant]